Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib In vivo

Inflammation

Volumn 35, Issue 4, 2012, Pages 1378-1391

  Mao, Xin ^a   Pan, Xiaoyun ^a   Zhao, Song ^a   Peng, Xiaochun ^a   Cheng, Tao ^a   Zhang, Xianlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Aseptic loosening; Bortezomib; Osteolysis; Titanium

Indexed keywords

BIOCHEMICAL MARKER; BORTEZOMIB; CD68 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEASOME; PROTEASOME INHIBITOR; TITANIUM; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BONE DISEASE; BONE METABOLISM; CALVARIA; CELL INFILTRATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; FEMALE; GRANULOMATOSIS; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY OSTEOLYSIS; MOUSE; NONHUMAN; OSTEOLYSIS; PROSTHESIS LOOSENING; PROTECTION; PROTEIN EXPRESSION; RANDOMIZATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; ARTHROPLASTY, REPLACEMENT; BORONIC ACIDS; FEMALE; INFLAMMATION; MICE; MICE, INBRED BALB C; OSTEOLYSIS; OSTEOPROTEGERIN; PROSTHESIS FAILURE; PROTEASOME INHIBITORS; PYRAZINES; RANDOM ALLOCATION; RANK LIGAND; TITANIUM; TNF RECEPTOR-ASSOCIATED FACTOR 6; VASCULAR ENDOTHELIAL GROWTH FACTORS;

MUS;

EID: 84866731076     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9451-8     Document Type: Article

References (52)

1. Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271-1286.
2. Wang, M., P. Sharkey, and R. Tuan. 2004. Particle bioreactivity and wearmediated osteolysis. The Journal of Arthroplasty 19(8): 1028-1038.
3. Ren, W.P., D.C. Markel, R. Zhang, X. Peng, B. Wu, H. Monica, and P.H. Wooley. 2006. Association between UHMWPE particleinduced inflammatory osteoclastogenesis and expression of RANKL, VEGF, and Flt-1 in vivo. Biomaterials 27(30): 5161-5169.
4. Al-Saffar, N., J. Mah, Y. Kadoya, and P.A. Revell. 1995. Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants. Annals of the Rheumatic Diseases 54(3): 201-208.
5. Ren, W., R. Zhang, D.C. Markel, B. Wu, X. Peng, M. Hawkins, and P.H. Wooley. 2007. Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis. Journal of Rheumatology 34(1): 27-35.
6. Markel, D.C., R. Zhang, T. Shi, M. Hawkins, and W. Ren. 2009. Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis. Inflammation Research 58(7): 413-421.
7. Zhang, W., Peng, X., Cheng, T., and Zhang, X. 2011. Vascular endothelial growth factor gene silencing suppresses wear debrisinduced inflammation. Int Orthop. Available from URL: http:// www.springerlink.com/content/ 86m1431q8035755q/ (doi:10.1007/s00264-011-1252-4).
8. Anandarajah, A.P. 2009. Role of RANKL in bone diseases. Trends in Endocrinology and Metabolism 20(2): 88-94.
9. Bord, S., D. Ireland, S. Beavan, and J. Compston. 2003. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32(2): 136-141.
10. Ye, H., J.R. Arron, B. Lamothe, M. Cirilli, T. Kobayashi, N.K. Shevde, D. Segal, O.K. Dzivenu, M. Vologodskaia, and M. Yim. 2002. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418(6896): 443-447.
11. Armstrong, A.P., M.E. Tometsko, M. Glaccum, C.L. Sutherland, D. Cosman, and W.C. Dougall. 2002. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. Journal of Biological Chemistry 277(46): 44347-44356.
12. Boyle, W.J., W.S. Simonet, and D.L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423(6937): 337-342.
13. Kobayashi, N., Y. Kadono, A. Naito, K. Matsumoto, T. Yamamoto, S. Tanaka, and J. Inoue. 2001. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO Journal 20(6): 1271-1280.
14. Elliott, P.J., and J.S. Ross. 2001. The proteasome. American Journal of Clinical Pathology 116(5): 637-646.
15. Wickner, S., M.R.Maurizi, and S. Gottesman. 1999. Posttranslational quality control: folding, refolding, and degrading proteins. Science 286(5446): 1888-1893.
16. Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348 (26): 2609-2617.
17. von Metzler, I., H. Krebbel, M. Hecht, R.A. Manz, C. Fleissner, M. Mieth, M. Kaiser, C. Jakob, J. Sterz, L. Kleeberg, U. Heider, and O. Sezer. 2007. Bortezomib inhibits human osteoclastogenesis. Leukemia 21(9): 2025-2034.
18. Heider, U., M. Kaiser, C. Müller, C. Jakob, I. Zavrski, C.O. Schulz, C. Fleissner, M. Hecht, and O. Sezer. 2006. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. European Journal of Haematology 77(3): 233-238.
19. Arpinati, M., G. Chirumbolo, B. Nicolini, C. Agostinelli, and D. Rondelli. 2008. Selective apoptosis of monocytes and monocytederived DCs induced by bortezomib (Velcade). Bone Marrow Transplantation 43(3): 253-259.
20. Rakshit, D.S., K. Ly, T.K. Sengupta, B.J. Nestor, T.P. Sculco, L.B. Ivashkiv, and P.E. Purdue. 2006. Wear debris inhibition of antiosteoclastogenic signaling by interleukin-6 and interferon-gamma mechanistic insights and implications for periprosthetic osteolysis. The Journal of Bone and Joint Surgery American 88(4): 788-799.
21. Wooley, P.H., R.Morren, J. Andary, S. Sud, S.Y. Yang, L.Mayton, D. Markel, A. Sieving, and S. Nasser. 2002. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 23(2): 517-526.
22. Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-Time quantitative PCR and the 2-CT method. Methods 25(4): 402-408.
23. Ren, W., D.C. Markel, R. Schwendener, Y. Ding, B. Wu, and P.H. Wooley. 2008. Macrophage depletion diminishes implant-wearinduced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043-1051.
24. Purdue, P.E., P. Koulouvaris, B.J. Nestor, and T.P. Sculco. 2006. The central role of wear debris in periprosthetic osteolysis. HSS Journal 2(2): 102-113.
25. Goodman, S.B., M. Trindade, T. Ma, M. Genovese, and R.L. Smith. 2005. Pharmacologic modulation of periprosthetic osteolysis. Clinical Orthopaedics and Related Research 430: 39-45.
26. Ren, W., X.H. Li, B.D. Chen, and P.H. Wooley. 2004. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-?B activity. Journal of Orthopaedic Research 22(1): 21-29.
27. Miyanishi, K., M.C.D. Trindade, T. Ma, S.B. Goodman, D.J. Schurman, and R.L. Smith. 2003. Periprosthetic osteolysis: induction of vascular endothelial growth factor from human monocyte/macrophages by orthopaedic biomaterial particles. Journal of Bone and Mineral Research 18(9): 1573-1583.
28. Senger, D.R., S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak. 1983. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (4587): 983-985.
29. Ferrara, N., and W.J. Henzel. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications 161(2): 851-858.
30. Leung, D.W., G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935): 1306-1309.
31. Min, J., Y. Kim, E. Kim, Y. Gho, I. Kang, S. Lee, Y. Kong, and Y. Kwon. 2003. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. Journal of Biological Chemistry 278(41): 39548-39557.
32. Wong, B., R. Josien, S. Lee, B. Sauter, H. Li, R. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. The Journal of Experimental Medicine 186(12): 2075-2080.
33. Leibbrandt, A., and J.M. Penninger. 2008. RANK/RANKL: Regulators of immune responses and bone physiology. Annals of the New York Academy of Sciences 1143(1): 123-150.
34. Mandelin, J., T.F. Li, M. Liljestrom, M. Kroon, R. Hanemaaijer, S. Santavirta, and Y.T. Konttinen. 2003. Imbalance of RANKL/ RANK/OPG system in interface tissue in loosening of total hip replacement. The Journal of Bone and Joint Surgery British 85(8): 1196-1201.
35. Haynes, D.R., T. Crotti, A. Potter, M. Loric, G.J. Atkins, D.W. Howie, and D.M. Findlay. 2001. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. The Journal of Bone and Joint Surgery. British Volume 83(6): 902-911.
36. Ren, W., R. Blasier, X. Peng, T. Shi, P.H. Wooley, and D. Markel. 2009. Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses. Bone 44(4): 671-677.
37. Bylski, D., C. Wedemeyer, J. Xu, T. Sterner, F. Löer, and M. von Knoch. 2009. Alumina ceramic particles, in comparison with titanium particles, hardly affect the expression of RANK-, TNF-A-, and OPG-mRNA in the THP-1 human monocytic cell line. Journal of Biomedical Materials Research. Part A 89(3): 707-716.
38. Granchi, D., G. Ciapetti, I.Amato, S. Pagani, E. Cenni, L. Savarino, S. Avnet, J. Peris, A. Pellacani, and N. Baldini. 2004. The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation. Biomaterials 25(18): 4037-4045.
39. Baumann, B., C. Rader, J. Seufert, U. Nöth, O. Rolf, J. Eulert, and F. Jakob. 2004. Effects of polyethylene and TiAIV wear particles on expression of RANK, RANKL and OPG mRNA. Acta Orthopaedica 75(3): 295-302.
40. Masui, T., S. Sakano, Y. Hasegawa, H. Warashina, and N. Ishiguro. 2005. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials 26(14): 1695-1702.
41. Inoue, J., T. Ishida, N. Tsukamoto, N. Kobayashi, A. Naito, S. Azuma, and T. Yamamoto. 2000. Tumor necrosis factor receptorassociated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Experimental Cell Research 254(1): 14.
42. Rauner, M., W. Sipos, and P. Pietschmann. 2006. Osteoimmunology. International Archives of Allergy and Immunology 143(1): 31-48.
43. Hongming, H., and H. Jian. 2009. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leukemia Research 33(1): 115-122.
44. Ang, E., N.J. Pavlos, S.L. Rea, M. Qi, T. Chai, J.P. Walsh, T. Ratajczak, M.H. Zheng, and J. Xu. 2009. Proteasome inhibitors impair RANKL-induced NF-?B activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and I?Ba signaling cascades. Journal of Cellular Physiology 220(2): 450-459.
45. Baldwin, L., B. Flanagan, P. McLaughlin, R. Parkinson, J. Hunt, and D. Williams. 2002. A study of tissue interface membranes from revision accord knee arthroplasty: The role of T lymphocytes. Biomaterials 23(14): 3007-3014.
46. Micklem, K., E. Rigney, J. Cordell, D. Simmons, P. Stross, H. Turley, B. Seed, and D. Mason. 1989. A human macrophageassociated antigen (CD68) detected by six different monoclonal antibodies. British Journal of Haematology 73(1): 6-11.
47. Anan, A., E.S. Baskin-Bey, H. Isomoto, J.L. Mott, S.F. Bronk, J.H. Albrecht, and G.J. Gores. 2006. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. American Journal of Physiology-Gastrointestinal and Liver Physiology 291(4): G709-G716.
48. Pagliari, L.J., H. Perlman, H. Liu, and R.M. Pope. 2000. Macrophages require constitutive NF-kappa B activation to maintain A1 expression and mitochondrial homeostasis. Molecular and Cellular Biology 20(23): 8855-8865.
49. Landgraeber, S., M. von Knoch, F. Loer, A. Wegner, M. Tsokos, and M. Totsch. 2008. Extrinsic and intrinsic pathways of apoptosis in aseptic loosening after total hip replacement. Biomaterials 29 (24-25): 3444-3450.
50. Mao, X., Pan, X., Cheng, T., and Zhang, X. 2011. Therapeutic potential of the proteasome inhibitor bortezomib on titanium particle-induced inflammation in a murine model. Inflammation. Available from URL: http://www.springerlink. com/content/ u5516224u6501835/ (doi:10.1007/s10753-011-9392-7).
51. Jimi, E., K. Aoki, H. Saito, F. D'Acquisto, M.J. May, I. Nakamura, T. Sudo, T. Kojima, F. Okamoto, and H. Fukushima. 2004. Selective inhibition of NF-kappaB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature Medicine 10(6): 617-624.
52. Hofbauer, L., D. Lacey, C. Dunstan, T. Spelsberg, B. Riggs, and S. Khosla. 1999. Interleukin-1 [beta] and tumor necrosis factor-[alpha], but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3): 255-259.